Type II endometrial cancer is mostly estrogen independent, arises from atrophic endometrium in postmenopausal patients, and is associated with p53 mutations, display inactivation of p16 and E-cadherin, alongside Human Epidermal growth factor Receptor 2 (HER2) amplification [4,5]. Here, CDH1 is linked to endometrial cancer.